Stock Jumping Abnormally High: Puma Biotechnology, Inc. (PBYI) – HugoPress

Puma Biotechnology, Inc. (PBYI)

Credit Suisse Maintains Puma Biotechnology, Inc. (PBYI)s stock to Outperform with the price target of $111. This rating was issued on 9/22/16. The stock recently closed its previous session at $37.25 by showing a percentage change of 1.09% from its previous day closing price of $36.85.

Price Target is basically a projection of future price of a companys stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Puma Biotechnology, Inc. (PBYI) in which Stifel Nicolaus Upgrades Puma Biotechnology, Inc. (PBYI) to Buy with no specific Price Target on 9/21/16. UBS Maintains the stock to Buy on 4/11/16 by stationing a price target of $60. JP Morgan Maintains the companys stock to Overweight on 3/29/16 by setting a price target of $89. RBC Capital Downgrades Puma Biotechnology, Inc. (PBYI) to Sector Perform with a price target of $36.

Puma Biotechnology, Inc. (PBYI) currently has a consensus Price Target of $68.67. While some analysts have a High Price target for the stock of $89 and a Low Price Target of $17.

Several sell side analysts reviewed their recommendations on Puma Biotechnology, Inc. (PBYI) where 3 analyst have rated the stock as Strong Buy, 2 analysts said its a Buy, 2 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 1.67. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Puma Biotechnology, Inc. (PBYI) reported its Actual EPS of $-2.04/share. The analysts offering Earnings Estimates for the company were believing that Puma Biotechnology, Inc. (PBYI) could bring EPS of $-1.92/share. The difference between Actual EPS and Estimated EPS was -0.12 Percent. Thus the company showed an Earnings Surprise of -6.3 Percent.

Puma Biotechnology, Inc. (PBYI) has a market capitalization of 1.38 Billion. The stock traded with the volume of 1.05 Million shares in the last trading session. The stock touched its high share price of $73.27 on 09/27/16 and the stock also touched its Lowest price in the last 52-weeks of trading on 05/10/16 as $19.74. The company has a 1 Year high price target of $68.67. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -0.58%. The Moving Average SMA50 is -1.4% while SMA200 is -13.56%.

Puma Biotechnology, Inc. (PBYI) is currently showing its ROA (Return on Assets) of -144.7%. The Return on Investment (ROI) is at 0% while its Return on Equity (ROE) value stands at -186.2%. The stock currently shows its YTD (Year to Date) performance of 21.34 percent while its Weekly performance value is 3.04%. The Monthly and Yearly performances are -16.2 percent and 14.09 percent respectively. The Relative Volume value measured for Puma Biotechnology, Inc. (PBYI) is 1.08. The Average Volume (3 months) is 976.87 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. PBYI has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 6 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.

Read the original post:
Stock Jumping Abnormally High: Puma Biotechnology, Inc. (PBYI) - HugoPress